INC Research Strengthens Leadership for Strategic Advisory Services Unit
(Thomson Reuters ONE) -
Robert Ryan, PhD, appointed Vice President, Regulatory Strategy, Consulting and
Submissions
Raleigh, N.C., Dec. 6, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, today announced the appointment of Robert Ryan, PhD, as Vice
President, Regulatory Strategy, Consulting and Submissions. Dr. Ryan will
provide global leadership to position INC Strategic Advisory Services as a
market leader in regulatory consulting and submissions offerings. In this role
he will continue to build on the Company's strong reputation in helping
biopharmaceutical customers worldwide navigate through the complexities of the
regulatory environment to accelerate their time to market.
"Robert brings a unique blend of strategic leadership skills and international
regulatory expertise that speaks to biopharmaceutical companies looking for
guidance along the entire continuum of the drug development lifecycle," said Tim
Dietlin, Senior Vice President, Global Consulting and Strategic Alliances. "Our
Regulatory Consulting and Submissions team has a long history of exceptional
work, and we look forward to continuing this track record under Robert's
leadership."
Dr. Ryan is an experienced senior regulatory affairs executive with more than
two decades of experience in the biopharmaceutical industry. He brings a unique
blend of scientific and business acumen to the position, having held regulatory
and executive leadership positions in both the CRO and biopharmaceutical
industries with companies such as Quintiles, PPD, Celtic Therapeutics and
Schwarz Pharma. Most recently, he was Chairman of the Board for Levare, LLC, a
CNS/pain pharmaceutical development company. Dr. Ryan has been directly involved
in the approval of more than 20 drugs throughout his career. He holds a
doctorate in toxicology from the University of North Carolina at Chapel Hill,
master's degrees in pharmacokinetics and genetics. Dr. Ryan is a diplomate of
the American Board of Toxicology.
With a network of global locations and on-the-ground expertise in all key
markets, INC Research is committed to delivering superior quality regulatory
services to help customers design the most efficient product development
programs. The Company supports customer needs across the entire product
lifecycle, from early regulatory development strategy consultations to clinical
trial and marketing authorization submissions and post-licensing support. INC
Research's service portfolio ranges from new chemical entities (NCEs) to
biologics, biosimilars, well-established substances 505(b)(2) pathway, generic
drugs, devices and in vitro diagnostics. With in-house expertise in drug-device
combination products and medical devices, the Company also is able to offer a
range of strategic and operational services, including clinical investigation
submissions and CE-marking (Conformité Européenne) expertise. For more
information on INC Research's Regulatory Consulting and Submissions services,
please visit the online Resource Library.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development programs
of the highest integrity. Pharmaceutical and biotechnology companies look to INC
Research for a complete range of customized Phase I through Phase IV programs in
all therapeutic areas and innovative pediatric and women's health trials. The
company's Trusted Process(®) methodology and therapeutic foresight lead
customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
Contact: Lori Dorer, Media +1 (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1663198]
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2012 - 17:57 Uhr
Sprache: Deutsch
News-ID 210514
Anzahl Zeichen: 4809
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 162 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Strengthens Leadership for Strategic Advisory Services Unit"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
